Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback

Fineline Cube Apr 27, 2026
Company Drug

Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design

Fineline Cube Apr 27, 2026
Company Drug

Simcere Zaiming Initiates US Phase I Study of SIM0500 for Relapsed/Refractory Multiple Myeloma

Fineline Cube Jun 19, 2025

China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary Simcere Zaiming announced the first patient dosing...

Drug Medical Device Policy / Regulatory

FDA Launches ‘Elsa’ AI Tool to Enhance Staff Efficiency in Regulatory Processes

Fineline Cube Jun 19, 2025

The U.S. Food and Drug Administration (FDA) announced the launch of an artificial intelligence (AI)...

Drug Policy / Regulatory

FDA Launches Immediate Review of Clinical Trials Involving Cell Transfer to Hostile Countries

Fineline Cube Jun 19, 2025

The U.S. Food and Drug Administration (FDA) this week announced an immediate review of new...

Company Drug

Gilead’s Yeztugo Approved by FDA as First Six-Monthly Injectable HIV PrEP

Fineline Cube Jun 19, 2025

US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that it has received market approval from the...

Company Drug

Fosun Pharma’s Fumaining Launches Clinically for Rare Disease Treatment in China

Fineline Cube Jun 19, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd.’s (HKG: 2196, SHA: 600196) in-house developed Category 1 drug...

Drug Policy / Regulatory

FDA Launches Commissioner’s National Priority Voucher Program for Accelerated Drug Reviews

Fineline Cube Jun 19, 2025

The U.S. Food and Drug Administration (FDA) this week announced the launch of the Commissioner’s...

Company Drug

Hengrui Pharma’s Ruitanning Enters Clinical Use for Chemo-Induced Nausea and Vomiting

Fineline Cube Jun 19, 2025

China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the prescription of its Category 1...

Company Drug

Merck’s Clesrovimab Gears Up for Priority Review in China for RSV Prevention

Fineline Cube Jun 19, 2025

China’s Center for Drug Evaluation (CDE) website indicates that US giant Merck, Sharp & Dohme’s...

Company Drug

Sanofi’s Tzield Prescribed in Boao Lecheng to Delay Onset of Type 1 Diabetes

Fineline Cube Jun 18, 2025

Tzield (teplizumab), the world’s first and only targeted therapy designed to delay the onset of...

Company Medical Device

Allgens Medical’s SkuHeal Artificial Bone Repair Material Gains Vietnam Marketing Approval

Fineline Cube Jun 18, 2025

Beijing-based regenerative medicine materials and implantable device maker Allgens Medical Technology Co., Ltd (SHA: 688613)...

Company Drug

Clover Biopharmaceuticals Completes Enrollment for Phase I Trial of RSV + hMPV Combination Vaccines

Fineline Cube Jun 18, 2025

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) announced the completion of enrollment for the first participants...

Company Deals

Shanghai Henlius Biotech Partners with Shanghai Chest Hospital for Clinical Research and Talent Development

Fineline Cube Jun 18, 2025

China’s Shanghai Henlius Biotech Inc., (HKG: 2696) this week entered into a strategic collaboration agreement...

Company Drug

RemeGen’s Telitacicept Receives Orphan Drug Designation for Myasthenia Gravis in Europe

Fineline Cube Jun 18, 2025

China-based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced that it has received orphan drug...

Company Drug

Yunnan Baiyao’s JZ-14 Gets NMPA Clinical Clearance for Ulcerative Colitis Trial

Fineline Cube Jun 18, 2025

Kunming-based Yunnan Baiyao Group Co., Ltd (SHE: 000538), traditionally known for Chinese medicine, announced clinical...

Company Drug

Johnson & Johnson Submits sBLA to Expand Stelara Use for Pediatric Crohn’s Disease

Fineline Cube Jun 18, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) this week submitted a supplemental Biologics License...

Company Drug

Suzhou Zelgen Gains NMPA Approval for ZG005 and ZG006 Combination Trial in Advanced Cancers

Fineline Cube Jun 18, 2025

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received clinical trial...

Company Medical Device

Mindray Bio-Medical Expands North American Warehouse to Enhance Operational Efficiency

Fineline Cube Jun 18, 2025

China-based Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) announced the groundbreaking of its North...

Company

GSK Launches ‘Linked by Lupus’ Initiative to Support Lupus Care with $1M Funding

Fineline Cube Jun 18, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced the launch of the Linked by Lupus:...

Company Drug

Bayer Files NDA for Gadoquatrane, Aiming to Offer Lowest-Dose GBCA in the U.S.

Fineline Cube Jun 18, 2025

Germany-based Bayer AG (ETR: BAYN) announced that it has made a New Drug Application (NDA)...

Company Deals

EpimAb Biotherapeutics Submits Hong Kong IPO Application as Biotech Expands

Fineline Cube Jun 18, 2025

Shanghai-based biotech EpimAb Biotherapeutics, Inc. has submitted a main board listing application to the Hong...

Posts pagination

1 … 132 133 134 … 657

Recent updates

  • Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets
  • Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease
  • Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback
  • China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio
  • Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Company

Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease

Company Drug

Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback

Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.